Clinical trials: Neoplasms by Site
Colorectal Cancer
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer: Continued Avastin Plus Chemotherapy After First Progression in Clinical Practice
This local, non-interventional, cohort study of patients with metastatic colorectal cancer (mCRC) will prospectively collect data from standard clinical practice of second-line treatment with chemotherapy plus Avastin…
- Trial name
- NCT02287597
- Where
- 4 sites in Croatia
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
Choroidal Melanoma, Indeterminate Lesions
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
- Conditions
- Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
- Trial name
- CoMpass (NCT06007690)
- Testing
- Bel-sar, Suprachoroidal Microinjector, Infrared Laser
- Where
- 53 sites in United States, Australia and 12 more
- Volunteers
- 108 people
- Sponsor
- Aura Biosciences
Metastatic Breast Cancer
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
This study was a Phase III, randomized, double-blind, placebo-controlled, multicenter international clinical trial conducted to investigate the use of pertuzumab in combination with trastuzumab and docetaxel as first-line…
- Trial name
- CLEOPATRA (NCT00567190)
- Testing
- Pertuzumab, Trastuzumab, Docetaxel
- Where
- 322 sites in United States, Argentina and 24 more
- Volunteers
- 808 people
- Sponsor
- Genentech, Inc.
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Early Breast Cancer
Arthralgia During Anastrozole Therapy for Breast Cancer
The purpose of this study is to describe the joint symptoms and structural joint changes under anastrozole as adjuvant treatment in postmenopausal women with early breast cancer.
- Trial name
- NCT00323479
- Testing
- Anastrozole
- Where
- 5 sites in France
- Volunteers
- 114 people
- Sponsor
- AstraZeneca
Breast Cancer
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab
The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both intravenous and oral panobinostat plus trastuzumab.
- Trial name
- NCT00567879
- Testing
- Panobinostat, Trastuzumab
- Where
- 20 sites in United States, Canada and 4 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Early Breast Cancer (Phase 2), Advanced Breast Cancer (Phase 1b)
Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer
PF-04691502 is an inhibitor of PI3K and mTOR kinase. Published data support the hypothesis that a PI3K/mTOR antagonist in combination with letrozole might mitigate the intrinsic or acquired resistance to hormonal therapy and…
- Trial name
- NCT01430585
- Testing
- PF-04691502, PF-04691502 in combination with Letrozole, Letrozole
- Where
- 5 sites in Belgium, Italy and 2 more
- Volunteers
- 14 people
- Sponsor
- Pfizer
Prostate Cancer
Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation
French epidemiological data have shown a heterogeneous distribution of the risk of mortality from prostate cancer according to region.
- Trial name
- FACT (NCT01729676)
- Testing
- Degarelix or GnRH agonist
- Where
- France
- Volunteers
- 315 people
- Sponsor
- Ferring Pharmaceuticals
Colorectal Neoplasm
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.
- Trial name
- NCT03384940
- Testing
- DS-8201a
- Where
- 25 sites in United States, Italy and 3 more
- Volunteers
- 86 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.
- Conditions
- Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation
- Trial name
- NCT04965818
- Testing
- Futibatinib and Binimetinib
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Taiho Oncology, Inc.
Prostatic Neoplasms
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.
- Trial name
- READY (NCT00744497)
- Testing
- Dasatinib, Docetaxel, Prednisone
- Where
- 186 sites in United States, Argentina and 23 more
- Volunteers
- 1,930 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
The LightPath® Breast Cancer Study
This study is a prospective, single arm, multi-centre study to evaluate the intra-operative use of the LightPath® Imaging System for the assessment of tumour margin status compared to hospital standard of care histopathology in…
- Trial name
- NCT02666079
- Testing
- LightPath® Imaging System.
- Where
- 5 sites in Poland, United Kingdom
- Volunteers
- 170 people
- Sponsor
- Lightpoint Medical Limited
Metastatic Ovarian Cancer, Triple Negative Breast Cancer
Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer
This is a Phase 1b, open-label, non-randomized, Dose Confirmation study. Subjects will be treated, once a week, with IV doses of Nerofe and low dose (20 mg/m2) Doxorubicin (6-8 hours from one another) in consecutive, 28-day…
- Trial name
- NCT03634150
- Testing
- Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.
- Where
- Israel
- Sponsor
- Immune System Key Ltd
Neoplasms, Breast
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
To characterize the effect of repeat oral dose of lapatinib treatment on the pharmacokinetics of a single oral and single intravenous dose of midazolam in adult cancer patients.
- Trial name
- NCT00258050
- Testing
- Midazolam, Lapatinib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
- Trial name
- NCT07361510
- Testing
- Pumitamig, Pembrolizumab
- Where
- 283 sites in United States, Argentina and 34 more
- Volunteers
- 750 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer, Colorectal Adenoma
Protocol to Validate the Performance of the LifeKit® Prevent Colorectal Neoplasia Test for CRC Screening
The purpose of this study is to determine the sensitivity and specificity for LifeKit Prevent Colorectal Neoplasia Test for colorectal cancer (CRC) and for adenoma, including advanced adenoma.
- Trial name
- PREVENT (NCT04693546)
- Testing
- LifeKit Prevent Colorectal Neoplasia Test, FIT Test
- Where
- United States
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Metabiomics Corp
Non Small Cell Lung Cancer
Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02317016
- Testing
- Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Rosuvastatin
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Malignant Neoplasm of Breast
ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes
Objectives of Clinical Trial The main objective of this clinical trial is to show the efficacy of fluorescence lymphangiography with indocyanine green (ICG) for the detection of sentinel lymph nodes.
- Trial name
- NCT01395706
- Testing
- ICG Fluorescence technique
- Where
- Germany
- Volunteers
- 125 people
- Sponsor
- Pulsion Medical Systems SE
Colorectal Cancer
Korean Red Ginseng in Treating Patients With Fatigue Caused by Chemotherapy for Colorectal Cancer
Korean Red Ginseng may improve fatigue in healthy subject. It is not yet known whether Korean Red Ginseng is effective compared with a placebo in chemotherapy.
- Trial name
- KRG (NCT02039635)
- Testing
- Korean Red Ginseng
- Where
- South Korea
- Volunteers
- 438 people
- Sponsor
- Korea Ginseng Corporation
Pancreatic Cancer
Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment
To evaluate the safety of two doses of Z-360 with Gemcitabine administration for subjects with unresectable advanced pancreatic cancer in order to determine the optimal dosage for PhaseII study
- Trial name
- NCT00288925
- Testing
- Z-360
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Zeria Pharmaceutical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.